Literature DB >> 1475519

Antigenic variation and strain heterogeneity in Borrelia spp.

B Wilske1, A G Barbour, S Bergström, N Burman, B I Restrepo, P A Rosa, T Schwan, E Soutschek, R Wallich.   

Abstract

Antigenic variation and strain heterogeneity have been demonstrated for the pathogenic Borrelia species, i.e. B. burgdorferi and the relapsing fever borreliae. In relapsing fever, new borrelia serotypes emerge at a high rate spontaneously, a mechanism that is caused by DNA rearrangements on linear plasmid translocating genes coding for variable major proteins from previous silent to expression sites (i.e. from inner sites to telomeric sites of the plasmid). As a result of this variation, the borreliae escape the immune response of the host, thus leading to the relapse phenomenon. In B. burgdorferi, which is the causative agent of the multisystem disorder Lyme borreliosis, there is also a growing body of findings that antigenic variation is involved in pathogenesis of the disease. Phenotypic variation of strains in vitro concerns the size and the amount of surface-associated proteins (OspA, OspB and pC). There are indications that OspA and OspB truncations are due to deletions within the ospAB operon caused by recombination events, and that OspA/OspB-less mutants lack the 49-kb plasmid that bears the ospAB operon. With the increasing number of isolates obtained from various geographic and biological sources, it became apparent that B. burgdorferi is immunologically and genetically more heterogeneous, as previously believed. The major outer surface proteins OspA and OspB (which have been efficient antigens in vaccine studies) are heterogeneous at a genetic level. The same degree of genetic non-identity was observed for the pC protein. Other proteins like flagellin and the highly specific immunodominant p100 range protein show a lower degree of non-identity. Recombinant OspA, pC, p100 range protein and flagellin have been hyperexpressed in E. coli and these proteins are immunologically reactive. This allows further research for development of vaccines and diagnostic tools. B. burgdorferi isolates have been investigated with genotyping (DNA hybridization, PCR and 16S rRNA analysis) as well as serotyping by various authors. Comparison of the different methods has shown good agreement when the same strains have been investigated. No correlation could be found between different phenotypic and genotypic groups with respect to the ability to cause arthritis in SCID mice. A serotyping system based on immunological differences in OspA detected by a panel of monoclonal antibodies has been proposed. Serotyping a large number of B. burgdorferi isolates has shown a striking predominance of the OspA serotype 2 among European isolates from human skin, in contrast to isolates from ticks or CSF.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1475519     DOI: 10.1016/0923-2508(92)90116-6

Source DB:  PubMed          Journal:  Res Microbiol        ISSN: 0923-2508            Impact factor:   3.992


  31 in total

1.  Efficacy of an OspA vaccine preparation for prevention of Lyme disease in New York State.

Authors:  G P Wormser; J Nowakowski; R B Nadelman; I Schwartz; D McKenna; D Holmgren; M Aguero-Rosenfeld
Journal:  Infection       Date:  1998 Jul-Aug       Impact factor: 3.553

2.  Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi.

Authors:  W T Golde; J Piesman; M C Dolan; M Kramer; P Hauser; Y Lobet; C Capiau; P Desmons; P Voet; D Dearwester; J C Frantz
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

3.  Cytopathic effects of the major surface protein and the chymotrypsinlike protease of Treponema denticola.

Authors:  J C Fenno; P M Hannam; W K Leung; M Tamura; V J Uitto; B C McBride
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

Review 4.  DNA fingerprinting of medically important microorganisms by use of PCR.

Authors:  A van Belkum
Journal:  Clin Microbiol Rev       Date:  1994-04       Impact factor: 26.132

Review 5.  Lyme disease vaccine.

Authors:  G P Wormser
Journal:  Infection       Date:  1996 Mar-Apr       Impact factor: 3.553

6.  Experimental Borrelia garinii infection of Japanese quail.

Authors:  E Isogai; S Tanaka; I S Braga; C Itakura; H Isogai; K Kimura; N Fujii
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

7.  Molecular cloning and immunological characterization of a novel linear-plasmid-encoded gene, pG, of Borrelia burgdorferi expressed only in vivo.

Authors:  R Wallich; C Brenner; M D Kramer; M M Simon
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

8.  Molecular and immunological characterization of a novel polymorphic lipoprotein of Borrelia burgdorferi.

Authors:  R Wallich; M M Simon; H Hofmann; S E Moter; U E Schaible; M D Kramer
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

9.  Molecular and evolutionary analyses of a variable series of genes in Borrelia burgdorferi that are related to ospE and ospF, constitute a gene family, and share a common upstream homology box.

Authors:  R T Marconi; S Y Sung; C A Hughes; J A Carlyon
Journal:  J Bacteriol       Date:  1996-10       Impact factor: 3.490

10.  Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen.

Authors:  W S Probert; R B LeFebvre
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.